1. Home
  2. ALLR vs RCG Comparison

ALLR vs RCG Comparison

Compare ALLR & RCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLR
  • RCG
  • Stock Information
  • Founded
  • ALLR 2004
  • RCG 1994
  • Country
  • ALLR United States
  • RCG United States
  • Employees
  • ALLR N/A
  • RCG N/A
  • Industry
  • ALLR Biotechnology: Pharmaceutical Preparations
  • RCG Investment Managers
  • Sector
  • ALLR Health Care
  • RCG Finance
  • Exchange
  • ALLR Nasdaq
  • RCG Nasdaq
  • Market Cap
  • ALLR 15.8M
  • RCG 18.2M
  • IPO Year
  • ALLR N/A
  • RCG N/A
  • Fundamental
  • Price
  • ALLR $1.73
  • RCG $2.59
  • Analyst Decision
  • ALLR Strong Buy
  • RCG
  • Analyst Count
  • ALLR 1
  • RCG 0
  • Target Price
  • ALLR $9.25
  • RCG N/A
  • AVG Volume (30 Days)
  • ALLR 641.5K
  • RCG 5.9K
  • Earning Date
  • ALLR 11-13-2025
  • RCG 01-01-0001
  • Dividend Yield
  • ALLR N/A
  • RCG 0.98%
  • EPS Growth
  • ALLR N/A
  • RCG N/A
  • EPS
  • ALLR N/A
  • RCG N/A
  • Revenue
  • ALLR N/A
  • RCG N/A
  • Revenue This Year
  • ALLR N/A
  • RCG N/A
  • Revenue Next Year
  • ALLR N/A
  • RCG N/A
  • P/E Ratio
  • ALLR N/A
  • RCG N/A
  • Revenue Growth
  • ALLR N/A
  • RCG N/A
  • 52 Week Low
  • ALLR $0.61
  • RCG $1.52
  • 52 Week High
  • ALLR $2.35
  • RCG $1.90
  • Technical
  • Relative Strength Index (RSI)
  • ALLR 58.71
  • RCG 47.72
  • Support Level
  • ALLR $1.54
  • RCG $2.54
  • Resistance Level
  • ALLR $1.65
  • RCG $2.64
  • Average True Range (ATR)
  • ALLR 0.13
  • RCG 0.07
  • MACD
  • ALLR -0.01
  • RCG 0.00
  • Stochastic Oscillator
  • ALLR 72.97
  • RCG 76.00

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.

About RCG RENN Fund Inc

RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.

Share on Social Networks: